Poster Abstract Session:
49. Antimicrobial Susceptibility and Resistance
Friday, October 21, 2011: 12:15 PM-2:15 PM
Room: Poster Hall B1

Learning Objectives:

none

Target Audience: Academicians, other

Topical Category: A. Antimicrobial agents and Resistance

Tracks: Pediatric ID, Adult ID

Presentations:

241
In Vitro Activity of Colistin (Polymyxin E) Versus Gram-negative Bacilli from Patients in Canadian Hospitals: Results of the CANWARD Study 2008-2010
Andrew Walkty, MD ; Melanie Baxter, MSc ; Heather J. Adam, PhD ; Kim Nichol, MSc ; James Karlowsky, PhD ; Daryl J. Hoban, PhD ; George G. Zhanel, PhD

242
Macrolide Resistance in Streptococcus pneumoniae in the United States and Canada – TEST 2008-2010
Samuel Bouchillon, MD ; Meredith Hackel, PhD ; Stephen Hawser, PhD ; Brian Johnson, BS ; Daryl Hoban, PhD ; Michael Dowzicky, MS

243
In Vitro Evaluation of Tigecycline against Drug-Resistant Enterococci and Staphylococcus aureus in North America – TEST 2007 - 2010
Samuel Bouchillon, MD ; Meredith Hackel, PhD ; Stephen Hawser, PhD ; Brian Johnson, BS ; Daryl Hoban, PhD ; Michael Dowzicky, MS

244
Tigecycline in Vitro Activity against Extended Spectrum Beta-Lactamase Producers in Latin America  – TEST 2008-2010
Samuel Bouchillon, MD ; Meredith Hackel, PhD ; Stephen Hawser, PhD ; Brian Johnson, BS ; Daryl Hoban, PhD ; Michael Dowzicky, MS

245
In Vitro Activity of Tigecycline against Commonly Isolated Pathogens of Skin and Skin Structure Infections in Latin America  – TEST 2007-2010
Sibylle Lob, MD, MPH ; Daryl Hoban, PhD ; Samuel Bouchillon, MD ; Robert Badal, BS ; Stephen Hawser, PhD ; Michael Dowzicky, MS

246
Impact of Cephalosporin and Carbapenem Breakpoint Revisions on Enterobacteriaceae Susceptibility Rates
Lynn Estes, PharmD ; Robin Patel ; Peggy Kohner, BS ; Ritu Banerjee, MD, PhD

247
Activities of Doripenem and Comparators with Important Gram-negative Pathogens in an In vitro MBEC™ Biofilm Model
Darren Abbanat, PhD ; Wenchi Shang, MS ; Karen Amsler, MS ; A. Simon Lynch, PhD

248
Continuing Rise in MICs for Colistin in Multi-drug Resistant Gram Negative Bacteria in Community Hospitals
Kevin McDonough, BS, PharmD , MPA ; Bhavna Desai, MT ; Josefa Deguino, MT ; Diana Finkel, DO

249
Extensively Drug-Resistant (XDR) and Pandrug-Resistant (PDR) Bacteria in the Post-Antibiotic Era: A Study on Epidemiology and Outcomes in a High-Prevalence Setting
Thomai Stardeli ; Olympia Samoglou ; Victoria Gouma ; Eirini Triantafyllaki ; Kostoula Arvaniti ; Eleni Siskou ; Vasiliki Koulourida ; Spiros Miyakis

251
In Vitro Minimum Bactericidal Concentration of Iodine against Emergent Surgical Pathogens
Kathryn Dormstetter, BS ; Linda Olson, BS ; Sally Bull, BS, CCRA

253
Potential Impact of Recommended Changes to Reporting Cephalosporin Minimum Inhibitory Concentrations for Extended Spectrum beta-Lactamase (ESBL) Pathogens
Mihai Iliesiu, MD ; Sugantha Iyer, MD ; Anilrudh Venugopal, MD ; Shrutika Vasudeva ; Joel Fishbain, MD

254
Antimicrobial Susceptibilities of Wound Isolates in Canada from 2007 to 2010: the CANWARD Surveillance Study
Jared M.P. Bullard, MD FRCPC ; Melanie Baxter, MSc ; Heather J. Adam, PhD ; Daryl J. Hoban, PhD ; George G. Zhanel, PhD

255
Variability in Susceptibility of Anaerobes Isolated from Different Body Sites – Results from the Tigecycline European Surveillance Trial, 2009 - 2010
Meredith Hackel, PhD ; Samuel Bouchillon, MD ; Stephen Hawser, PhD ; Brian Johnson, BS ; Daryl Hoban, PhD ; Michael Dowzicky, MS

257
Activity Profile of Anti-Pseudomonal Agents in Areas with Elevated Beta-lactam Resistant P. aeruginosa in the US; Results from CAPITAL Surveillance
Chris Pillar ; Jennifer Deane ; A. Simon Lynch, PhD ; R.K. Flamm, PhD ; Todd A. Davies ; Janet Peterson, PhD ; Clyde Thornsberry ; Dan Sahm

258
Surveillance Trends in the in Vitro Activity of Tigecycline, TEST 2004 to 2010: A Global Perspective
Daryl Hoban, PhD ; Samuel Bouchillon, MD ; Meredith Hackel, PhD ; Jack Johnson, MS, MBA ; Stephen Hawser, PhD ; Michael Dowzicky, MS

260
Trends in Susceptibility of Tigecycline against Selected Gram-Negative European Pathogens (TEST 2004 – 2010)
Stephen Hawser, PhD ; Samuel Bouchillon, MD ; Robert Badal, BS ; Jack Johnson, MS, MBA ; Michael Dowzicky, MS

261
Plasmid-Mediated Multidrug-resistance in Gram-Negative Bacteria Isolated from a New Hospital in Iraq
Xiaozhe Huang, PhD ; Mohamad Chahine, MD ; Julie Ake, MD, MSc ; Melissa Barber, AS, MLT (AMT) ; Emil Lesho, DO

262
Evaluation of Clinically Important Gram-negative and Gram-positive Isolates in Alabama: Electronically Captured 2007-2010 State-Wide Antibiogram
Andrew Madon, Pharm D ; Vikas Gupta, Pharm.D., BCPS ; Olivia Peeden, MPH ; Hollace Whitlock, MPH ; Phillip Francis, MD, MS ; RS Johannes, MD, MS

264
Clindamycin and Erythromycin Resistance in Colonizing Group B Streptococcus (2007-2009).
Frank Martilotti ; Angela Diskin ; Padma Nandula ; Barbara Robinson-Dunn, PhD ; Bobby Boyanton ; Bishara Freij, MD ; Graham Krasan

265
Cephalosporin Susceptibility Levels of Extended-Spectrum β-Lactamase Genotypes in Latin America
Robert Badal, BS ; Meredith Hackel, PhD ; Christine Lascols, MS ; Samuel Bouchillon, MD ; Daryl Hoban, PhD

266
Title: Daptomycin Non-Susceptible Staphylococcus aureus
Alexander Velazquez, MD ; C. Andrew DeRyke, Pharm.D. ; Valerie J. Hoover, MTASCP ; Dina Besece, PharmD ; Mark R. Wallace, MD

268
Carbapenem-Resistant Enterobacteriaceae (CRE) in Hennepin and Ramsey Counties, Minnesota: 30-Day Laboratory Surveillance
Edwin C Pereira, MD ; Paula M Snippes Vagnone, MT (ASCP) ; Kristin M Shaw, MPH ; Jane Harper, RN ; Ruth Lynfield, MD

269
The Incidence of Drug Resistant Escherichia coli Urine Isolates Varies by Age and Location of Onset:  a Population-based Study from Olmsted County, MN
Sanjeev Swami, MD ; Juliette Liesinger, BA ; Barbara Yawn, MD, MSc ; Nilay Shah, PhD ; Ritu Banerjee, MD, PhD

270
Resistance to common antimicrobial agents among E. coli isolates from acute uncomplicated cystitis in Seattle, 1998-2010
Ann Stapleton, MD ; Marsha Cox, MS ; Amanda White, BS ; Thomas Hooton, MD, FIDSA

CME Credits:

ACPE Credits:

ACPE Number:


<< Previous Session | Next Session >>

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.